• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis.

作者信息

Yew W W, Chau C H, Wen K H

出版信息

Int J Tuberc Lung Dis. 2008 Mar;12(3):345-6.

PMID:18284844
Abstract
摘要

相似文献

1
Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis.利奈唑胺治疗“难治性”耐多药结核病
Int J Tuberc Lung Dis. 2008 Mar;12(3):345-6.
2
Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.每日半剂量利奈唑胺治疗难治性耐多药结核病。
Int J Antimicrob Agents. 2009 Jan;33(1):92-3. doi: 10.1016/j.ijantimicag.2008.06.014. Epub 2008 Sep 11.
3
Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.关于《每日300毫克利奈唑胺治疗难治性耐多药和广泛耐药结核病》的评论
J Antimicrob Chemother. 2009 Oct;64(4):879-83; author reply 883-4. doi: 10.1093/jac/dkp265. Epub 2009 Aug 3.
4
Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.关于《每日300毫克利奈唑胺治疗难治性耐多药和广泛耐药结核病》的评论
J Antimicrob Chemother. 2009 Nov;64(5):1119; author reply 1119-20. doi: 10.1093/jac/dkp291. Epub 2009 Aug 8.
5
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response.每日300毫克利奈唑胺剂量用于治疗难治性耐多药和广泛耐药结核病——作者回应
J Antimicrob Chemother. 2009 Nov;64(5):1119-20. doi: 10.1093/jac/dkp344. Epub 2009 Sep 10.
6
[A hope for multidrug-resistant tuberculosis?].
Rev Med Suisse. 2008 Oct 15;4(175):2233.
7
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.每日300毫克利奈唑胺剂量用于治疗难治性耐多药和广泛耐药结核病。
J Antimicrob Chemother. 2009 Aug;64(2):388-91. doi: 10.1093/jac/dkp171. Epub 2009 May 25.
8
Fatal lactic acidosis after prolonged linezolid exposure for treatment of multidrug-resistant tuberculosis.长期使用利奈唑胺治疗耐多药结核病后发生致命性乳酸酸中毒。
Eur J Intern Med. 2009 Oct;20(6):e134-5. doi: 10.1016/j.ejim.2008.12.002. Epub 2009 Jan 23.
9
Optic neuropathy secondary to Linezolid for multidrug-resistant mycobacterial spinal tuberculosis.利奈唑胺继发视神经病变用于耐多药分枝杆菌性脊柱结核
Ocul Immunol Inflamm. 2015 Feb;23(1):90-2. doi: 10.3109/09273948.2013.874447. Epub 2014 Jan 16.
10
Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.利奈唑胺治疗耐多药结核病患者的治疗药物监测中的有限采样策略。
Ther Drug Monit. 2010 Feb;32(1):97-101. doi: 10.1097/FTD.0b013e3181cc6d6f.

引用本文的文献

1
Linezolid for drug-resistant pulmonary tuberculosis.利奈唑胺用于耐药性肺结核
Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD012836. doi: 10.1002/14651858.CD012836.pub2.
2
Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis.利奈唑胺对患有危及生命的结核性脑膜炎的患者显示出迅速且显著的治疗效果。
Antimicrob Agents Chemother. 2014 Oct;58(10):6297-301. doi: 10.1128/AAC.02784-14. Epub 2014 Aug 4.
3
Linezolid in the treatment of extensively drug-resistant tuberculosis.
利奈唑胺治疗广泛耐药结核病。
Infection. 2014 Aug;42(4):705-11. doi: 10.1007/s15010-014-0632-2. Epub 2014 Jun 6.
4
Assessment of linezolid efficacy, safety and tolerability in the treatment of tuberculosis: A retrospective case review.评估利奈唑胺治疗结核病的疗效、安全性和耐受性：回顾性病例研究。
Can J Infect Dis Med Microbiol. 2013 Fall;24(3):e50-2. doi: 10.1155/2013/535616.
5
Challenges in the development of drugs for the treatment of tuberculosis.抗结核药物研发面临的挑战。
Braz J Infect Dis. 2013 Jan-Feb;17(1):74-81. doi: 10.1016/j.bjid.2012.10.009. Epub 2013 Jan 1.
6
Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.应用干血斑法分析治疗耐多药结核病患者的利奈唑胺血药浓度。
Antimicrob Agents Chemother. 2012 Nov;56(11):5758-63. doi: 10.1128/AAC.01054-12. Epub 2012 Aug 27.
7
Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.生物标志物辅助剂量选择用于结核治疗的 PNU-100480 早期开发的安全性和疗效。
Antimicrob Agents Chemother. 2011 Feb;55(2):567-74. doi: 10.1128/AAC.01179-10. Epub 2010 Nov 15.
8
Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.两种利奈唑胺剂量方案在耐多药和广泛耐药结核病患者中的药代动力学比较。
Clin Pharmacokinet. 2010 Aug;49(8):559-65. doi: 10.2165/11532080-000000000-00000.
9
Current development and future prospects in chemotherapy of tuberculosis.结核病化疗的现状与展望。
Respirology. 2010 Jul;15(5):764-78. doi: 10.1111/j.1440-1843.2010.01775.x. Epub 2010 Jun 4.
10
Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.用于耐多药（MDR）和广泛耐药（XDR）结核病管理的二线和三线抗结核药物的临床药理学及病灶穿透特性
Curr Clin Pharmacol. 2010 May;5(2):96-114. doi: 10.2174/157488410791110797.